Determining the Impact of HIV on the Severity of COVID-19 Infection: 2020–2021 Nationwide Analysis

Authors: *Antony Arumairaj,¹ Phool Iqbal,¹ Joseph Mattana,² Shobhana Chaudhari,² Fnu Samaksh,¹ Thomas Newman¹

- New York Medical College/Metropolitan Hospital Center, New York, USA
- Department of Medicine, New York Medical College/Metropolitan Hospital Center, New York USA
- *Correspondence to antojack99@gmail.com

Disclosure: The authors have declared no conflicts of interest.

Keywords: COVID-19 infection, HIV, invasive ventilation, length of stay, mortality rate.

Citation: Respir AMJ. 2025;3[1]:62-64. https://doi.org/10.33590/respiramj/LPUJ4805

BACKGROUND

HIV causes immunodepression, which can lead to severe outcomes of COVID-19 infection. However, clinical studies have shown conflicting reports regarding outcomes of COVID-19 infection in patients with HIV. This National Inpatient Sample (NIS) study aimed to determine the impact of HIV on the severity of outcomes in patients with COVID-19 infection.¹⁻³

METHODS

The authors identified patients hospitalized with COVID-19 infection who had a history of HIV using the 2020–2021 NIS database. STATA/MP 17.0 software (StataCorp, College Station, Texas, USA) was used for statistical analysis. Multivariate logistic regression analysis was performed.

RESULTS

There were 818,011 patients hospitalized with COVID-19 infection, and 36,232 patients hospitalized with a history of HIV. The patients with COVID-19 infection were stratified based on their HIV status. There were 815,979 patients with COVID-19 who did not have HIV, and 2,032 patients who had both COVID-19 and HIV (Table 1). White people constituted the largest ethnic group in the category of COVID-19 infection without HIV, while African American people constituted the largest ethnic group in the category of COVID-19 infection with HIV. Hispanic people constituted the second largest group in both categories. Patients in the lowest national income quartile and those with Medicaid insurance constituted the largest group among the national income quartile and insurance groups, respectively. The length of hospital stay among patients with COVID-19 and HIV was 10.4 days. For those without HIV, it was 8.2 days, with a p value of <0.001. The mortality rate was 13.1% among patients with COVID-19 but without HIV. For those with HIV, it was 13.3%, with a p value of 0.72. The unadjusted odds ratio (OR) of mortality in patients with COVID-19 and HIV was 1.02. The adjusted OR of mortality, after adjustment for age, sex, race, Charlson Comorbidity Index (CCI), national income quartile, and insurance, was 0.53, with a p value of <0.001. This indicated that the mortality rate among patients with COVID-19 and HIV was significantly lower than those without HIV (Table 2). The unadjusted OR of invasive ventilation in patients with COVID-19 and HIV was 1.26, while the adjusted OR was 0.50, with a p value of <0.001. This indicated that the need for invasive ventilation among patients with COVID-19 and HIV was significantly lower compared to those without HIV.



CONCLUSION

The authors' analysis of the NIS database suggests that HIV was not a major risk factor for severe COVID-19 infection.

Patients with COVID-19 infection and HIV had longer lengths of stay. However, they had a lower need for invasive ventilation and a lower mortality rate than those without HIV.

Table 1: Demographic and clinical characteristics, 2020–2021 National Inpatient Sample database.

Variables	COVID-19 infection without HIV (N=815,979)	COVID-19 infection with HIV (N=2,032)	p value
Age	61.7	53.3	<0.001
Sex			
Male %	51.7%	70.9%	<0.001
Female %	48.3%	29.1%	
Mortality	13.1%	13.3%	0.716
LOS	8.2 days	10.4 days	<0.001
Ethnicity			
White	57.2%	19.9%	<0.001
African American	17.4%	51.6%	
Hispanic	18.0%	21.9%	
Asian/Pacific Islander	2.9%	1.1%	
Native American	0.9%	0.5%	
Other	3.6%	5%	
National Income Quartile			
1–38,999	33.1%	48.7%	<0.001
39,000-47,999	27.2%	24.2%	
48,000-62,999	23.0%	16.1%	
>63,000	16.7%	11.0%	
Insurance			
Medicaid	49.9%	38.7%	<0.001
Medicare	15.7%	36.2%	
Private	30.4%	19.2%	
Uninsured	4.1%	5.9%	
Charlson Comorbid Index			
0	31.0%	0%	<0.001
1	25.5%	0%	
2	15.4%	0%	
≥3	28.0%	100%	

LOS: length of stay.



Table 2: Outcomes-adjusted odds ratio.

	Odds ratio (95% CI)	p value
Invasive ventilation	0.50 (0.43-0.57)	<0.001
Mortality	0.53 (0.45-0.62)	<0.001

References

- Danwang C et al. Outcomes of patients with HIV and COVID-19 co-infection: a system-atic review and meta-analysis. AIDS Res Ther. 2022;19(1):3.
- Del Amo J et al. Incidence and severity of COVID-19 in HIV-positive persons receiving an-tiretroviral therapy. Ann Intern Med. 2021;174(4):581-2.
- Arumairaj A et al. Determining the Impact of Human Immunodeficiency Virus (HIV) on the Severity of COVID-19 Infection: 2020-2021 Nationwide Analysis. Abstract 6618. ATS International Conference, May 16-21, 2025.